Funding will Support Expanded Commercialization Efforts for PreciseBreast Risk Assessment

资金将支持扩大商业化工作，以进行精确的风险评估

PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, today announced that it has raised $20.7 million in Series B funding, bringing its total funding to date to $31.5 million. The round was led by Eventide Asset Management (Eventide), which invests in biotech and life science healthcare companies seeking solutions for unmet clinical needs..

。本轮由Eventide Asset Management（Eventide）牵头，该公司投资于生物技术和生命科学保健公司，寻求未满足临床需求的解决方案。。

Additional participants in the round include Labcorp, Quest Diagnostics, and GenHenn Capital Venture, along with existing investors.

这一轮的其他参与者包括Labcorp、Quest Diagnostics和GenHenn Capital Venture，以及现有投资者。

“Our team continues to advance breast cancer diagnostics by delivering faster, more accurate data, in a cost-efficient method. This allows clinical care teams to make better informed clinical decisions resulting in improved patient outcomes,” said Eric Converse, Founding Board Member at PreciseDx. “This capital infusion sets the stage for our next phase of continued in-depth clinical trials to validate PreciseBreast in a specific clinical setting and market entry point.”.

PreciseDx创始董事会成员埃里克·匡威（EricConverse）表示：“我们的团队通过以经济高效的方法提供更快，更准确的数据，继续推进乳腺癌诊断。这使临床护理团队能够做出更明智的临床决策，从而改善患者的预后。”。“这次资金注入为我们下一阶段的持续深入临床试验奠定了基础，以验证特定临床环境和市场进入点的准确性。”。

“We’re excited about PreciseDx, the milestones accomplished to date, and the potential for improving patient care in the near future,” said Westley Dupray, CFA, Research Analyst, Principal at Eventide. “We expect this financing will help accelerate the validation process for PreciseBreast and its potential to improve patient risk assessments, clinical outcomes, and healthcare efficiency.”.

“我们对PreciseDx、迄今为止完成的里程碑以及在不久的将来改善患者护理的潜力感到兴奋，”Eventide首席财务官、研究分析师Westley Dupray说。“我们预计这笔资金将有助于加速PreciseBreast的验证过程及其改善患者风险评估，临床结果和医疗保健效率的潜力。”。

The funding comes on the heels of a number of key achievements by PreciseDx, including the completion of two successful validation studies (analytical and clinical), receipt of CLIA Standard approval and CLEP NYSDOH review on the PreciseBreast assessment, a Cost Impact Study published by the Journal of Medical Economics, and the addition of new key collaborations, such as UCLA, COTA and Baptist Health South Florida, and Baylor Scott & White Health..

在获得这笔资金之前，PreciseDx 已经取得了一系列重要成就，包括成功完成了两项验证研究（分析和临床），获得了 CLIA 标准批准和 NYSDOH 对 PreciseBreast 评估的 CLEP 审查，在《医学经济学杂志》（Journal of Medical Economics）上发表了《成本影响研究》（Cost Impact Study），并与加州大学洛杉矶分校（UCLA）、COTA 和南佛罗里达浸信会健康中心（Baptist Health South Florida）以及贝勒斯科特与怀特健康中心（Baylor Scott & White Health）等机构建立了新的重要合作关系。

“Securing Series B funding not only signals PreciseDx’s continued achievements but also underscores the trust and confidence in the Company’s trajectory,” added Converse.

“Converse补充说："获得B轮融资不仅标志着PreciseDx不断取得成就，也彰显了人们对公司发展轨迹的信任和信心。

Aquilo Partners, L.P. acted as financial advisor and McDermott Will & Emery as legal advisor to PreciseDx.

Aquilo Partners，L.P.担任PreciseDx的财务顾问，McDermott Will＆Emery担任法律顾问。

About PreciseDx

关于PreciseDx

PreciseDx is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis. Combining AI with our patented Morphology Feature Array (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

PreciseDx正在创新肿瘤学诊断，利用人工智能（AI）进行革命性的形态学驱动的疾病分析。PreciseDx将人工智能与我们获得专利的形态学特征阵列（MFA）相结合，可以获得无与伦比的疾病见解和准确可行的智能，从而在整个癌症护理过程中做出更全面的决策。

To learn more about PreciseDx, visit precisedx.ai..

要了解有关PreciseDx的更多信息，请访问PreciseDx.ai。。

About PreciseBreast

关于PreciseBreast

PreciseBreast is an early-stage invasive breast cancer risk assessment, independent of HER2, and hormone receptor status. The AI-powered test utilizes standard H&E pathology slide images. Leveraging millions of data points, PreciseBreast analyzes, correlates, and quantifies those critical features that predict breast cancer recurrence and delivers a Risk of Recurrence Score.

PreciseBreast是一种早期浸润性乳腺癌风险评估，与HER2和激素受体状态无关。人工智能测试利用标准的H＆E病理幻灯片图像。利用数百万个数据点，PreciseBreast分析，关联和量化预测乳腺癌复发并提供复发风险评分的关键特征。

The test meets the rigorous Clinical Laboratory Improvement Amendments (CLIA) standards and has passed the Clinical Laboratory Evaluation Program (CLEP) Assay Validation Review by the New York State Department of Health (NYSDOH). PDxBr will be available worldwide under the brand name of PreciseBreast.

该测试符合严格的临床实验室改进修正案（CLIA）标准，并已通过纽约州卫生部（NYSDOH）的临床实验室评估计划（CLEP）分析验证审查。。

For more information, please contact precisebreast@precisedx.ai..

有关更多信息，请联系precisebreast@precisedx.ai..

Originally announced August 21st, 2024

最初于2024年8月21日宣布

TagsAquilo Partners L.P. Eric Converse Eventide Eventide Asset Management GenHenn Capital Venture Health IT Funding Health IT Fundings Health IT Investment LabCorp McDermott Will & Emery PreciseDx Quest Diagnostics Westley Dupray

TagsAquilo Partners L.P.Eric Converse Eventide Eventide资产管理GenHenn Capital Venture Health IT Funding Health IT Fundings Health IT Investment LabCorp McDermott Will&Emery PreciseDx Quest Diagnostics Westley Dupray

Get Fresh Healthcare & IT Stories Delivered Daily

每天提供新鲜的医疗保健和IT故事

Join thousands of your healthcare & HealthIT peers who subscribe to our daily newsletter.

加入成千上万订阅我们每日新闻稿的healthcare&HealthIT同行。

We respect your privacy and will never sell or give out your contact information

我们尊重您的隐私，绝不出售或泄露您的联系信息